Medical Oncology

Papers
(The H4-Index of Medical Oncology is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Oncotype DX testing does not affect clinical practice in stage IIa colon cancer44
The genomic architecture of metastasis in breast cancer: focus on mechanistic aspects, signalling pathways and therapeutic strategies44
The immunomodulatory effects of Candida albicans isolated from the normal gastrointestinal microbiome of the elderly on colorectal cancer28
The role of inflammatory indices in the outcome of COVID-19 cancer patients27
The combined therapy of miR-383-5p restoration and paclitaxel for treating MDA-MB-231 breast cancer27
COVID-19 pandemic: a new cause of unplanned interruption of radiotherapy in breast cancer patients24
Can the host immune response against SARS-CoV2 also cause an anticancer effect?20
PSMA: a game changer in the diagnosis and treatment of advanced prostate cancer20
Regulatory mechanisms of heme regulatory protein BACH1: a potential therapeutic target for cancer20
How to ensure uninterrupted treatment of radiotherapy patients during delta variants of SARS-CoV-2 virus epidemic: the latest experience from Xi’an, China20
Identification of the role of mono-ADP-ribosylation in colorectal cancer by integrated transcriptome analysis19
Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy18
Notch signaling in oral pre-cancer and oral cancer17
The “collateral damage” of the war on COVID-19: impact of the pandemic on the care of epithelial ovarian cancer17
Enhancement of Apo2L/TRAIL signaling pathway receptors by the activation of Klotho gene with CRISPR/Cas9 in Caco-2 colon cancer cells17
The inhibition of Panc1 cancer cells invasion by hAMSCs secretome through suppression of tyrosine phosphorylation of SGK223 (at Y411 site), c-Src (at Y416, Y530 sites), AKT activity, and JAK1/Stat3 si16
DNMT1 and miRNAs: possible epigenetics footprints in electromagnetic fields utilization in oncology16
0.11042284965515